Excalipoint

About Excalipoint

Excalipoint Biotech focuses on next-generation cancer immunotherapy platforms, including trispecific antibody platforms, T cell engager prodrug platforms, and T cell immune shield platforms. The company develops innovative solutions to enable targeted T cell–mediated therapies and broaden clinical applications in immuno-oncology. Based in Shanghai, China, it emphasizes strategic platforms that advance antibody engineering and cell-based therapies for cancer treatment.